Next Article in Journal
The Role of miRNAs in Angiogenesis, Invasion and Metabolism and Their Therapeutic Implications in Gliomas
Next Article in Special Issue
Integrins and Exosomes, a Dangerous Liaison in Cancer Progression
Previous Article in Journal / Special Issue
Integrin αvβ3 Signaling in Tumor-Induced Bone Disease
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessFeature PaperReview
Cancers 2017, 9(7), 83;

Potential of Integrin Inhibitors for Treating Ovarian Cancer: A Literature Review

Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka Suita, Osaka 5650871, Japan
Author to whom correspondence should be addressed.
Academic Editor: Helen M. Sheldrake
Received: 10 June 2017 / Revised: 30 June 2017 / Accepted: 3 July 2017 / Published: 8 July 2017
(This article belongs to the Special Issue Integrins in Cancer)
Full-Text   |   PDF [897 KB, uploaded 8 July 2017]   |  


Epithelial ovarian cancer is a fatal disease, with a cure rate of only 30%. Several recent studies have targeted integrins for cancer treatment. Preclinical studies have shown the effectiveness of several integrin inhibitors for blocking cancer progression, especially by blocking angiogenesis. Because the initial critical step in ovarian cancer metastasis is the attachment of cancer cells to the peritoneum or omentum and because clinical trials have provided positive results for anti-angiogenic therapy, therapies targeting integrins may be the most feasible approach for treating cancer. This review summarizes the current understanding of integrin biology in ovarian cancer metastasis and various therapeutic approaches involving integrin inhibitors. However, no integrin inhibitor has shown favorable results thus far. However, conjugates of cytotoxic agents with the triplet sequence arginine-glycine-aspartate (RGD) peptides targeting α5β1-, αvβ3-, and αvβ6-integrins may be promising integrin-targeting therapies for further clinical investigation. View Full-Text
Keywords: integrin; ovarian cancer; angiogenesis; RGD peptide; volociximab integrin; ovarian cancer; angiogenesis; RGD peptide; volociximab

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Kobayashi, M.; Sawada, K.; Kimura, T. Potential of Integrin Inhibitors for Treating Ovarian Cancer: A Literature Review. Cancers 2017, 9, 83.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top